Press release

Cancer Core Europe proudly announces the appointment of Professor Fabien Calvo as Chief Scientific officer

An appointment reflecting the ambitions of Cancer Core Europe

As of December 1, 2014, Professor Fabien Calvo is employed by Gustave Roussy Cancer Campus Grand Paris as the Chief Scientific Officer for Cancer Core Europe.

Fabien Calvo, MD PhD, is currently Professor of Pharmacology at University of Paris Denis Diderot Medical School and Physician at Saint Louis Hospital in Paris. He is specialized in the field of genomics and the biology of metastatic disease, translational research, preclinical pharmacology and early clinical trials in haematology and oncology.

His role as Cancer Core Europe Chief Scientific Officer will be to organize and coordinate activities for this new European network, specifically working closely with the co-chairs, the Steering Group and the other scientific officers involved. Fabien Calvo will also assist the consortium in developing a global vision and planning and delivering the implementation of the strategy.

From April 2007 to September 2014, Fabien Calvo was Deputy Director General of the National Cancer Institute of France (INCa), in charge of Research and Innovation Programs. Fabien Calvo was also during this period the director of the Cancer Multi-Organization Institute of the National Alliance for Life Sciences and Health (Aviesan), which includes INSERM, CNRS, CEA, INRA, INRIA, IRD, Pasteur Institute, Universities and University hospitals. He also launched with the USA, Canada, UK and Germany, the International Cancer Genoma Consortium in 2008 and the global alliance for genomics and clinics.

He was previously a resident and senior registrar of Paris Hospitals, and a research associate of the National Cancer Institute in Bethesda (NIH / NCI / DCT, USA).

From 1995, he was the Director and founder of the Inserm Clinical Investigation Center at the Saint-Louis Hospital. He was also the Director of Inserm Unit 716, working on the identification of new molecular targets for cancer treatment. He is a board member of the post-graduate school "fundamental basis of carcinogenesis". He has published more than 200 original and review articles.

Fabien Calvo worked as a coordinator of the cancer mission for the Director of the Research and Innovation department, Ministry of Research and Higher Education (2006-2007).
Cancer Core Europe strengthens its position in cancer research continuum challenge

Launched in July 2014, Cancer Core Europe is the consortium comprising six leading cancer centers in Europe to develop a common structure for research and healthcare to accelerate the development of new cancer treatments and precision medicine.

The consortium associates six comprehensive cancer centers: Gustave Roussy Cancer Campus Grand Paris (Villejuif – France), Cambridge Cancer research UK Centre (Cambridge, United Kingdom), Karolinska Institutet – KI (Stockholm, Sweden), Netherlands Cancer Institute – NKI (Amsterdam, The Netherlands), Vall d’Hebron Institute of Oncology – VHIO (Barcelona, Spain) and the German Cancer Research Center – DKFZ and its National Center for Tumor Diseases – NCT (Heidelberg, Germany).

A critical mass of activity for the successful integration of all cancers care information, clinical research and outcome research

Yearly within the Cancer Core Europe consortium circa 60.000 newly cancer patients are diagnosed, 300.000 cancer treatments are delivered and an estimated 1.000.000 outpatients visits are performed. More than 1.500 (?) clinical trials are being conducted at these six cancer centers annually. Together with the strengths in basic and translational cancer research, this structure will represent and harness a major force in European cancer research.

One of the objectives of Cancer Core Europe is the creation of a virtual single “e-hospital”: a powerful translational platform that integrates all patient files using a common software platform that federates the databases from each of the centers; inter-compatible clinical molecular profiling laboratories with a robust underlying computational biology pipeline; standardized functional and molecular imaging; commonly agreed SOPs for liquid and tissue biopsy procurement, storage and processing, for molecular diagnostics, “omics”, functional genetics, immune-monitoring; a culture of data collection and storage that facilitates complete longitudinal data sets and the conduct of outcome research.

As a working consortium, Cancer Core Europe is a great translational platform to bridge “bench-to-bedside and bedside-to-bench” also for conducting next-generation clinical trials focused on proof-of-concept, predictive and resistance monitoring biomarkers.

Discover more about the six Cancer Core Europe consortium partners:

. Cambridge Cancer Centre: www.cambridgecancercentre.org.uk
. Karolinska Institutet: www.ki.se
. Netherlands Cancer Institute: www.nki.nl
. Vall d’Hebron Institute of Oncology: www.vhio.net
. DKFZ-NCT: www.dkfz.de

Press contacts:

. Gustave Roussy:
  virginie.renoisade@gustaveroussy.fr – +33 1 42 11 50 59 – +33 6 17 66 00 26
  christine.lascombe@gustaveroussy.fr – +33 1 42 11 41 75 – +33 6 26 36 76 17